ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Sumitomo Dainippon sets sights on new-strategy cancer drugs

OSAKA -- Sumitomo Dainippon Pharma is gearing up to develop a new class of biopharmaceutical cancer drugs, hoping for a successful product that can serve as a stable source of revenue once its antipsychotic drug Latuda goes off patent in 2019.

Starting in 2018, a U.S. subsidiary will begin clinical trials on a nucleic-acid medication based on the subsidiary's recently patented aiRNA technology. In this approach, short strands of so-called asymmetrical interfering RNA are synthesized for a method known as RNA interference to attack cancer cells by silencing specific genes.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more